Table 4 Summary of treatment-emergent adverse events that occurred ≥3% in any treatment group
Pateclizumab | ADA | Placebo | |
|---|---|---|---|
(n = 86) | (n = 85) | (n = 43) | |
Pharyngitis | 7 (8.1%) | 7 (8.2%) | 4 (9.3%) |
Headache | 3 (3.5%) | 11 (12.9%) | 2 (4.7%) |
Urinary tract infection | 7 (8.1%) | 7 (8.2%) | 2 (4.7%) |
Hypertension | 5 (5.8%) | 5 (5.9%) | 1 (2.3%) |
Nasopharyngitis | 4 (4.7%) | 4 (4.7%) | 3 (7.0%) |
Anemia | 5 (5.8%) | 3 (3.5%) | 2 (4.7%) |
Diarrhea | 2 (2.3%) | 5 (5.9%) | 3 (7.0%) |
Alanine aminotransferase increased | 2 (2.3%) | 3 (3.5%) | 4 (9.3%) |
Rheumatoid arthritis | 3 (3.5%) | 3 (3.5%) | 3 (7.0%) |
Gastroenteritis | 3 (3.5%) | 3 (3.5%) | 1 (2.3%) |